For example, it has been found that neoantigen-reactive CD8+ T cells are also those that are positive for PD-1, not only suggesting the possibility of utilizing these tumor-reactive T cells for future neoantigen identification, but also for elucidating the immunological mechanisms in which cancer cell tolerance still results despite appropriate neoantigen recognition. This evidence concerns the gene CD8A and neoplasm.